Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
Compare

CALA vs. CMRA, STAB, SYRS, ADTX, and SMFL

Should you buy Calithera Biosciences stock or one of its competitors? Calithera Biosciences's main competitors and comparable companies include Comera Life Sciences (CMRA), Statera Biopharma (STAB), Syros Pharmaceuticals (SYRS), Aditxt (ADTX), and Smart for Life (SMFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calithera Biosciences compare to Comera Life Sciences?

Calithera Biosciences (NASDAQ:CALA) and Comera Life Sciences (NASDAQ:CMRA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Comera Life Sciences Neutral

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Calithera Biosciences has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.

How does Calithera Biosciences compare to Statera Biopharma?

Statera Biopharma (NASDAQ:STAB) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Statera Biopharma has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Summary

Statera Biopharma and Calithera Biosciences tied by winning 1 of the 2 factors compared between the two stocks.

How does Calithera Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Calithera Biosciences Neutral

Calithera Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Calithera Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Calithera Biosciences N/A N/A N/A

Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Summary

Syros Pharmaceuticals beats Calithera Biosciences on 5 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Calithera Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Calithera Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Calithera Biosciences N/A N/A N/A

Given Calithera Biosciences' higher possible upside, analysts clearly believe Calithera Biosciences is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aditxt has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Aditxt Neutral
Calithera Biosciences Neutral

Calithera Biosciences has lower revenue, but higher earnings than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.14-$41.71M-$100.79 thousandN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Calithera Biosciences beats Aditxt on 6 of the 11 factors compared between the two stocks.

How does Calithera Biosciences compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Smart for Life has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Smart for Life has a beta of 15.1, suggesting that its stock price is 1,410% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Calithera Biosciences N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Calithera Biosciences Neutral

Summary

Smart for Life beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A743.86602.4391.76
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net Income-$39.65M$2.77B$3.45B$347.60M

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
STAB
Statera Biopharma
N/A$0.00
+100.0%		N/A+100.0%$3KN/AN/A20
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-90.9%$3K$386KN/A120
ADTX
Aditxt
0.0693 of 5 stars		$0.00
-3.6%		N/A-100.0%$2K$14.34KN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The Shocking Discovery Investigators Found Hidden Inside America's Port Cranes
U.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...
Altimetry | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel